# US 2024/0002884 A1 · Oncolytic virus vector and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002884 A1
- Document ID: US20240002884A1
- Status: Published application
- Kind: A1
- Application number: 18/349,983
- Filed: 2023-07-11
- Published: 2024-01-04
- Earliest claimed: 2021-06-03
- Assignees: Shanghai Yunying Biopharmaceutical Technology Co., Ltd.
- Applicants: Shanghai Yunying Biopharmaceutical Technology Co., Ltd.
- Inventors: Ziying GONG; Daoyun ZHANG; Yonghua SUN; Yi WANG; Nan SHI; Jun ZHU; Miao DING
- Web page: https://patentgrep.com/patent/US20240002884A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 35/763: Herpes virus
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C07K 14/035: Herpes simplex virus I or II
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 2039/505: {comprising antibodies}
- C12N 2710/16043: viral genome or elements thereof as genetic vector
- C12N 2710/16621: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The embodiments of the present disclosure may provide an oncolytic virus vector and an application thereof. The oncolytic virus vector may comprise a recombinant nucleic acid. The recombinant nucleic acid may include: (i) a first nucleic acid fragment encoding a soluble PD-1 molecule; (ii) a second nucleic acid fragment encoding a CD86 molecule; and (iii) a third nucleic acid fragment encoding an antibody to a CD3 molecule.

## Claims

### Claim 1

An oncolytic virus containing a recombinant nucleic acid, wherein the recombinant nucleic acid comprises:
(i) a first nucleic acid fragment encoding a soluble PD-1 molecule;
(ii) a second nucleic acid fragment encoding a CD86 molecule;
(iii) a third nucleic acid fragment encoding an antibody to a CD3 molecule; and
(iv) a fourth nucleic acid fragment encoding a US11 protein, wherein:
the oncolytic virus is an HSV-1 virus, and
the recombinant nucleic acid has a sequence of SEQ ID NO: 5.

### Claim at position 2

2-16. (canceled)

### Claim 17 (depends on 1)

A composition for treating cancers, wherein the composition comprises the oncolytic virus according to claim 1 and a pharmacologically acceptable vector or excipient; and wherein the cancers are non-small cell lung cancers, liver cancers, breast cancers, pancreatic cancers, or colon cancers.

### Claim at position 4

18-19. (canceled)

### Claim 20 (depends on 17)

The composition of claim 17, wherein the composition is used for treating the non-small cell lung cancers or the colon cancers.

### Claim 21 (depends on 1)

An application of the oncolytic virus of claim 1 in preparation of a drug for treating cancers, wherein the cancers are non-small cell lung cancers, liver cancers, breast cancers, pancreatic cancers, or colon cancers.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The application of claim 21, wherein the cancers are the non-small cell lung cancers or the colon cancers.

### Claim at position 9

24-32. (canceled)
